Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals.

Clara GalvisAlejandro ColmenaresLina CabralesLinda IbatáJuliana MarulandaOscar OvalleDionisio PuelloCatherine RojasMartha AfricanoAdriana BallesterosHéctor Posso

Published in: Pediatric pulmonology (2022)

The hospitalization rate and the need for NICU admission were lower than those reported in the literature. In this real-life setting, palivizumab appears to be effective in preventing serious cases of RSV infection.

Keyphrases

respiratory syncytial virus
preterm infants
low birth weight
systematic review
emergency department
healthcare
gestational age